Site-dependent response to chemotherapy for carcinoma of the breast.
作者信息
Whitehouse J M
出版信息
J R Soc Med. 1985;78 Suppl 9(Suppl 9):18-22.
Abstract
摘要
相似文献
1
Site-dependent response to chemotherapy for carcinoma of the breast.
J R Soc Med. 1985;78 Suppl 9(Suppl 9):18-22.
2
Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Clin Breast Cancer. 2002 Dec;3(5):346-52. doi: 10.3816/CBC.2002.n.038.
3
A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer.
Ann Oncol. 2002 Nov;13(11):1730-6. doi: 10.1093/annonc/mdf290.
4
Treatment with eribulin (halaven) in heavily pre-treated patients with metastatic breast cancer.
Acta Oncol. 2014 Sep;53(9):1275-7. doi: 10.3109/0284186X.2014.918277. Epub 2014 May 20.
5
Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial.
BMC Cancer. 2005 Feb 22;5:21. doi: 10.1186/1471-2407-5-21.
6
[The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient].
Gan To Kagaku Ryoho. 1995 May;22(6):799-804.
7
Compassionate use of humanized anti-HER2/neu protein, trastuzumab for metastatic breast cancer in Japan.
Breast Cancer. 2001;8(4):310-5. doi: 10.1007/BF02967530.
8
[Results of tamoxifen-medroxyprogesterone acetate sequential therapy in 22 patients with recurrent breast cancer].
Gan To Kagaku Ryoho. 1989 Nov;16(11):3555-8.
9
[A case report of advanced breast cancer with remarkable response to chemoendocrine therapy (CTF + MPA)].
Gan To Kagaku Ryoho. 1998 Apr;25(5):739-42.
10
[Clinical trial of UFT against disseminated breast cancer].
Gan To Kagaku Ryoho. 1984 Nov;11(11):2381-5.
引用本文的文献
1
Treating bony metastases.
BMJ. 1991 Aug 24;303(6800):429-30. doi: 10.1136/bmj.303.6800.429.
本文引用的文献
1
Chemotherapy of metastatic carcinoma of the breast.
Clin Radiol. 1980 Jul;31(4):433-6. doi: 10.1016/s0009-9260(80)80184-x.
2
Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity.
Cancer. 1983 Jun 1;51(11):1998-2004. doi: 10.1002/1097-0142(19830601)51:11<1998::aid-cncr2820511107>3.0.co;2-u.
3
Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project.
J Clin Oncol. 1984 Jun;2(6):643-51. doi: 10.1200/JCO.1984.2.6.643.
4
Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio.
Cancer. 1984 May 1;53(9):1836-40. doi: 10.1002/1097-0142(19840501)53:9<1836::aid-cncr2820530906>3.0.co;2-p.
5
Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival.
Cancer Treat Rep. 1980 Jan;64(1):111-6.
6
Cyclical combination chemotherapy for advanced breast carcinoma.
Br Med J. 1974 Feb 9;1(5901):218-20. doi: 10.1136/bmj.1.5901.218.
7
Proceedings: Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma. A Southwest Cancer Chemotherapy study Group study.
Cancer. 1974 Feb;33(2):519-26. doi: 10.1002/1097-0142(197402)33:2<519::aid-cncr2820330229>3.0.co;2-x.
8
Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer.
Cancer. 1975 Jul;36(1):90-7. doi: 10.1002/1097-0142(197507)36:1<90::aid-cncr2820360104>3.0.co;2-h.
9
An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer.
Cancer. 1975 Apr;35(4):1101-7. doi: 10.1002/1097-0142(197504)35:4<1101::aid-cncr2820350413>3.0.co;2-m.
10
Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962) and cyclophosphamide therapy of drug-resistant metastatic breast carcinoma.
Cancer. 1977 Sep;40(3):987-93. doi: 10.1002/1097-0142(197709)40:3<987::aid-cncr2820400304>3.0.co;2-0.
Zotero 插件